SS
UNCY icon

SBI Securities’s Unicycive Therapeutics UNCY Stock Holding History

SBI Securities’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.61K Hold
557
– – ﹤0.01% 2468
2026
Q1 		$3.67K Sell
557
-1
-0.2% -$7 ﹤0.01% 2162
2025
Q4 		$3.22K Sell
558
-2
-0.4% -$11 ﹤0.01% 2209
2025
Q3 		$2.44K Buy
560
+7
+1% +$31 ﹤0.01% 2347
2025
Q2 		$2.64K Buy
553
+550
+18,333% +$3.4K ﹤0.01% 2274
2025
Q1 		$14 Sell
3
-2
-40% -$12 ﹤0.01% 3922
2024
Q4 		$39 Buy
+5
New +$28 ﹤0.01% 3689

Other funds holding UNCY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

SBI Securities's UNCY Position: Q2 2026 in Review

SBI Securities held its Unicycive Therapeutics (UNCY) position steady in Q2 2026 at 557 shares worth $2.61K. The position accounts for ﹤0.01% of the portfolio, ranked #2468.

SBI Securities first reported a position in UNCY in Q4 2024 and has held it in 7 quarters since. The position peaked at $3.67K in Q1 2026. 80 funds tracked by Wall St. Rank hold UNCY as of Q2 2026.

  • SBI Securities held 557 shares of Unicycive Therapeutics worth $2.61K as of Q2 2026.
  • SBI Securities left its Unicycive Therapeutics share count unchanged in Q2 2026.
  • Unicycive Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #2468 holding.
  • SBI Securities first reported a position in Unicycive Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Unicycive Therapeutics position peaked at $3.67K in Q1 2026.
  • 80 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.